Bioventus BVS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $132.09M+6.6% | $157.9M+2.8% | $138.65M-0.2% | $147.66M-2.4% | $123.88M-4.3% | ||
| $41.32M+1.2% | $49.12M-3.7% | $44.42M-2.2% | $45.57M-4.2% | $40.82M-0.6% | ||
| $90.77M+9.3% | $108.78M+6.0% | $94.23M+0.7% | $102.09M-1.5% | $83.06M-6.0% | ||
| 68.7%+1.7pp | 68.9%+2.1pp | 68%+0.6pp | 69.1%+0.6pp | 67%-1.2pp | ||
| $2.47M-18.1% | $3.01M-8.1% | $2.92M-23.9% | $3.17M-24.7% | $3.01M+14.6% | ||
| $78.33M+6.6% | $82.76M-4.7% | $78.66M-3.5% | $79.11M-18.2% | $73.5M-6.7% | ||
| $1.11M-30.5% | $1.3M-26.6% | $1.4M-32.3% | $1.44M-30.3% | $1.59M-9.2% | ||
| $454K— | —— | —— | —— | $0— | ||
| $8.42M+72.8% | $19.49M— | $11.25M+209% | $18.37M+158% | $4.87M-1.2% | ||
| 6.4%+2.4pp | 12.3%— | 8.1%+5.5pp | 12.4%+33.3pp | 3.9%+0.1pp | ||
| -$4.33M+42.4% | -$5.31M+41.0% | -$6.18M+35.2% | -$7.49M+24.5% | -$7.51M+27.4% | ||
| -$3.9M+52.9% | -$5.34M+31.1% | -$6.58M+26.1% | -$8.06M+20.1% | -$8.29M+20.3% | ||
| $0+100% | $0+100% | $1K— | -$1K— | -$81K— | ||
| $4.52M+232% | $14.14M+26,785% | $4.67M+189% | $10.31M+125% | -$3.42M+37.6% | ||
| $571K+701% | -$3.18M— | $664K+12.7% | $1.04M+114% | -$95K-110% | ||
| $3.11M+218% | $14.76M+3,903% | $3.16M+161% | $7.46M+129% | -$2.64M+46.1% | ||
| 2.4%+4.5pp | 9.3%+9.6pp | 2.3%+6.0pp | 5.1%+22.0pp | -2.1%+1.6pp | ||
| $0.04+200% | $0.21— | $0.05+163% | $0.11+127% | -$0.04+50.0% | ||
| $0.05+225% | $0.22— | $0.05+163% | $0.11+127% | -$0.04+50.0% | ||
| 70M+6.1% | 68.9M+6.8% | 68.8M+5.5% | 68.5M+7.0% | 66M+4.1% | ||
| 67.3M+2.0% | 66.6M+3.2% | 66.9M+2.6% | 66.5M+3.8% | 66M+4.1% | ||
| -$4.33M+42.4% | -$5.31M+41.0% | -$6.18M+35.2% | -$7.49M+24.5% | -$7.51M+27.4% | ||
| $2.73M+229% | $14.69M+531% | $2.09M+144% | $8.75M+134% | -$2.13M+60.3% | ||
| $0+100% | $0+100% | $1K— | -$1K— | -$81K— | ||
| $1M— | -$206K— | -$785K— | $0— | $0— | ||
| -$1.47M-332% | $108K+103% | -$528K-192% | $1.59M+474% | $633K+208% | ||
| —— | -$5.25K-61.5% | -$5.25K-61.5% | -$5.25K-61.5% | -$5.25K-61.5% | ||
| $427K+155% | -$37K-103% | -$79K-113% | -$561K-253% | -$777K-1,133% | ||
| $132.09M+6.6% | $157.9M+2.8% | $138.65M-0.2% | $147.66M-2.4% | $123.88M-4.3% | ||
| $8.42M+72.8% | $19.49M+315% | $11.25M+209% | $18.37M+158% | $4.87M-1.2% | ||
| $19.62M+17.3% | $31.18M+829% | $22.66M+42.3% | $30.42M+265% | $16.73M+0.1% | ||
| $19.62M+17.3% | $31.18M+829% | $22.66M+42.3% | $30.42M+265% | $16.73M+0.1% | ||
| 14.9%+1.3pp | 19.7%+17.6pp | 16.3%+4.9pp | 20.6%+32.8pp | 13.5%+0.6pp | ||
| $8.42M+72.8% | $19.49M+315% | $11.25M+209% | $18.37M+158% | $4.87M-1.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Bioventus's revenue?
- Bioventus (BVS) generated $576.3M in revenue over the trailing twelve months, up 1.5% year over year.
- Is Bioventus profitable?
- Bioventus reported $28.5M in net income over the trailing twelve months, a 4.9% net margin.
- What are Bioventus's profit margins?
- Gross margin is 68.7% and operating margin is 10.0%, with a 4.9% net margin.
- What is Bioventus's earnings per share?
- Bioventus's diluted EPS over the trailing twelve months is $0.41.
- Where does Bioventus's income statement data come from?
- Every line is extracted from Bioventus's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
